C4 Therapeutics

C4 Therapeutics is a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation.

C4 Therapeutics is harnessing the power of the body to control the quality of proteins within cells.

C4 Therapeutics was founded in 2016 by Marc Cohen. The company is headquartered in Watertown, Massachusetts.

 

C4’s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. The company's approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.

 

C4 Therapeutics' targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity.

 

C4 Therapeutics is backed by Cobro Ventures, Perceptive Advisors, Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, 3E Bioventures Capital, HBM Healthcare Investments, Lightchain Capital, Logos Capital and others. The company raised $170M ($150M in Series B and $20M in debt) in a new round on June 16, 2020. This brings C4T's total funding to $243M to date.

 

 

  • Year founded: 2016
  • Funding Info: $243M over 3 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Watertown
  • State: Massachusetts
  • Country: United States
Related businesses